Akebia’s Anemia Drug Disappoints In Mid-Stage COVID-19 Study
Akebia Therapeutics Inc (NASDAQ:AKBA) announced initial findings from an investigator-sponsored study evaluating vadadustat for Acute Respiratory Distress Syndrome (ARDS) with COVID-19…